Skip Navigation



British Medical Bulletin Advance Access published online on November 8, 2009
British Medical Bulletin, doi:10.1093/bmb/ldp040
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leung, A. Y. H.
Right arrow Articles by Kwong, Y.-L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leung, A. Y. H.
Right arrow Articles by Kwong, Y.-L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies

Anskar Y. H. Leung and Yok-Lam Kwong*

Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong, China

* Correspondence to: Y.-L. Kwong, Department of Medicine, Queen Mary Hospital, Pokfulam Road, Hong Kong, China. E-mail: ylkwong{at}hkucc.hku.hk

Introduction: Haematopoietic stem cell transplantation (HSCT) is potentially curative for haematological diseases. New developments are improving its applicability and success.

Sources of data: A literature search was conducted on peripheral blood haematopoietic stem cell (PBHSC) mobilization, umbilical cord blood (UCB) transplantation, reduced intensity conditioning (RIC) and acute graft-versus-host disease (aGVHD).

Areas of agreement: PBHSC mobilization by granulocyte colony-stimulating factor and chemomobilization may fail in up to 30% of patients previously treated with extensive chemotherapy. New mobilization agents, notably the CXCR4 antagonist, have improved mobilization efficacy. UCB-HSCT is equally feasible in children and adults. RIC enables HSCT to be performed in patients who are elderly or with serious medical co-morbidities. RIC-HSCT is associated with increased frequency of graft failure and disease relapse. The prophylaxis and treatment of aGVHD are still problematic.

Areas of controversy: Novel strategies in PBHSC mobilization, utilization of UCB-HSCT and RIC-HSCT and prophylaxis and treatment of aGVHD, have not been critically appraised or compared with conventional strategies.

Areas timely for developing research: The safety and efficacy of novel mobilization agents have to be tested in normal allogeneic donors. Methods of increasing the cell dose or efficacy of UCB should be developed, to extend its use to adults. RIC-HSCT should be compared with conventional HSCT in young patients. Continuous efforts in defining the best prophylaxis and treatment of aGVHD should be made.

Keywords: haematopoietic stem cell transplantation • reduced intensity conditioning • umbilical cord blood • mobilization • graft-versus-host disease

Accepted for publication October 3, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.